-+ 0.00%
-+ 0.00%
-+ 0.00%

Stephens & Co. Reiterates Overweight on Palvella Therapeutics, Maintains $220 Price Target

Benzinga·05/21/2026 15:25:49
Listen to the news
Stephens & Co. analyst Sudan Loganathan reiterates Palvella Therapeutics (NASDAQ:PVLA) with a Overweight and maintains $220 price target.